Recent Updates
Recently added Catalysts
XLO Positive Sentiment

Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Wednesday, August 28, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Xilio Therapeutics, a biotechnology company focused on immuno-oncology therapies, has announced its participation in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference. Renée Russo, the CEO of Xilio, will engage in a fireside chat scheduled for September 4, 2024, at 7:00 am EDT. This presentation will provide insights into the company's developments and research on cancer treatments. The event underscores Xilio's ongoing commitment to advancing cancer therapy options.
Price reaction · baseline $12.7386 (2024-08-27 close) · hit after-hours · clean, no other XLO news in the window
day 0 close
-11%
day 1
-11.7%
day 3 · peak
-18.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Xilio Therapeutics will present at a significant global healthcare conference.
  • Participation highlights the company's focus on tumor-activated immuno-oncology therapies.
  • The event provides a platform to connect with investors and share updates.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+66%
120-day peak, hindsight
Typical move
21.2%
average across 4 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
XTX501
Phase 1 · Metastatic NSCLC - Non-Small Cell Lung Cancer

Full Press Release Details

WALTHAM, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024, at 7:00 am EDT.
A live webcast can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at https://ir.xiliotx.com/. A replay of the webcast will be archived on the website for 30 days following the presentation.
About Xilio Therapeutics
Investor and Media Contact:

Frequently Asked Questions

When will Xilio Therapeutics' CEO participate in the conference?

René Russo will participate on September 4, 2024, at 7:00 am EDT.

How can I access the live webcast of the event?

The live webcast can be accessed on the Xilio Therapeutics website under 'Events & Presentations.'

How long will the webcast replay be available?

The webcast replay will be archived for 30 days after the presentation.

What type of therapies does Xilio Therapeutics develop?

Xilio Therapeutics focuses on tumor-activated immuno-oncology therapies.

Who can I contact for investor relations at Xilio Therapeutics?

You can contact their Vice President, Investor Relations via email at investors@xiliotx.com.

ShareAdd on Google
Tags: XLO Viatris Investor Conferences Healthcare Xilio Therapeutics immuno-oncology Morgan Stanley healthcare conference cancer treatments
Last updated: Aug 28, 2024

Biotech snapshot

Cash runway
$136M liquidity · $6M/mo burn
~22 mo
Low dilution risk
Lead asset
XTX501Phase 1
Metastatic NSCLC - Non-Small Cell Lung Cancer →

Catalyst track record

+66%
best trade around XLO's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for XLO.

See every catalyst's timing & PoA →